The effect of electric stimulation through skin and duloxetine on diabetic neuropathic pai

Phase 2

Recruiting

• Conditions: Diabetic Peripheral Neuropathy.; Type 2 diabetes mellitus with diabetic neuropathy, unspecified; E11.40

• Registration Number: IRCT20110413006186N13
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

patients type I or II diabetes mellitus, with diabetic neuropathic pain
Resistant to usual drug treatments, at least for 6 months
Minimum Pain Rating 4 based on Numerical Rating
Having normal creatinine and CBC blood counts
HBA1C less than 8%.

Exclusion Criteria

Having a pacemaker or defibrillator
Having brain stimulators
Infection or inflammation at the site of electrodes
Other neuropathies with causes other than diabetes
Alcohol consumption history
Malignant history
Tens Records history
Pregnancy
Bipolar patients
Duloxetine contraindications such as liver or kidney failure and MAO-I simultaneous use

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain caused by diabetic peripheral neuropathy. Timepoint: Before starting treatment, 1 month and 3 months after starting treatment. Method of measurement: Patients will be assessed based on NRS (Numerical Rating Scale).